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CC BY-NC-ND license (http://creativeAbstract Lamivudine, telbivudine, and entecavir are the first-line drugs covered by the
Taiwan National Health Insurance as 3-year treatments for patients with chronic hepatitis B vi-
rus (HBV), but the optimal treatment duration of each remains unclear. We aimed to detect
HBV treatment-cessation durability, and compare the predictors in patients with and without
clinical relapse. In this retrospective cohort study, 210 patients with chronic HBV who tested
hepatitis B e-antigen positive or hepatitis B e-antigen negative were treated for 3 years with a
nucleos(t)ide analogue. Of these, 102 patients continued therapy after 3 years, while 88 pa-
tients stopped treatment and were followed for 1 year due to financial difficulties. Efficacy
was assessed in terms of alanine aminotransferase (ALT) level normalization, HBV DNA clear-
ance, virus breakthrough, clinical relapse, and liver decompensation. The durability predictors
were evaluated by host factors, HBV DNA, and drug differences. Eighty patients (14 on lamivu-
dine, 19 on telbivudine, and 47 on entecavir) were recruited. There was no difference in
clinical-relapse rate among lamivudine, telbivudine, and entecavir (35.7% vs. 36.8% vs.
31.9%, respectively; p Z 0.916), and liver decompensated hepatitis was absent. In baseline
clinical characteristics, there were no differences between the clinical-relapse and nonrelapse
groups in age, sex, cirrhosis, prior treatment, HBV DNA, pretreatment ALT, or hepatitis B e-an-
tigen (HBeAg). The mean 3rd year serum ALT level differed significantly between clinical-eclare no conflicts of interest.
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Off-treatment durability and predictors in HBV 11relapse and nonrelapse patients (37.5 U/L vs. 27.7 U/L, respectively; p Z 0.044). The 3-year
nucleos(t)ide analogue off-treatment in patients with chronic HBV delivered according to the
Taiwan National Health Insurance guidelines had an overall 33.8% 1-year clinical-relapse rate
without any decompensated hepatitis flare-ups.
Copyright ª 2015, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).Introduction
Chronic hepatitis B virus (HBV) infection is an important
clinical problem worldwide due to its adverse outcomes,
including liver cirrhosis, hepatic decompensation, and he-
patocellular carcinoma. According to the Asian-Pacific
consensus statement on the management of HBV, lam-
ivudine (LAM), adefovir (ADV), entecavir 0.5 mg (ETV),
telbivudine (LdT), and tenofovir (TDF) can all be considered
initial therapy options for patients with HBV [1]. In Taiwan,
LAM, ETV, LdT, and TDF are the popular first-line nucleos(t)
ide analogues covered by the National Health Insurance
(NHI) as 3-year treatments for patients with chronic HBV,
while ADV and ETV 1 mg are reserved as second-line drugs
for virus breakthrough. These recommendations in Taiwan
differ somewhat from the European Association for the
Study of the Liver and the American Association for the
Study of Liver Diseases guidelines because of insurance
budget problems [2,3].
ETV and TDF are more effective in suppressing viral
levels and in improving biochemical and histological disease
features, but the ideal therapy duration, which criteria
should be stopped, and the long-term safety and efficacy
data are lacking [4]. Based on the guidelines of Asian Pacific
Association for the Study of the Liver, stop nucleos(t)ide
analogue therapy can be considered if undetectable HBV
DNA on three separate occasions at least 6 months apart in
HBeAg-negative patients, or serum HBeAg seroconversion in
HBeAg-positive patients. According to previous studies,
HBeAg seroconversion is an imperfect end point in antiviral
treatment because of the high cumulative virological
recurrence rate after its discontinuation [5,6]. In Taiwan,
some patients with HBV had to stop antiviral drug treat-
ment due to economic problems, while decompensated
hepatitis flare-up is a continuous concern of patients and
doctors.
In this retrospective cohort study from our clinical
practice, we provided patients with chronic HBV with
3 years of nucleos(t)ide analogue off-treatment, and fol-
lowed them for 1 year to evaluate its efficacy. Our aim was
to investigate the differences between the clinical-relapse
and nonrelapse groups.Methods
Patients and study procedure
This retrospective cohort study was approved by the Insti-
tutional Review Board of Mackay Memorial Hospital, Taipei,Taiwan (15MMHIS014). We recruited patients from the
hepatology clinics of Taipei Mackay Memorial Hospital who
had chronic HBV treated according to the Taiwan NHI
clinical practice guideline [HBsAg-positive and all HBeAg-
negative patients with an HBV DNA level > 2000 IU/mL and
a serum alanine transaminase (ALT) level > 80 IU/L for
3 months, all HBeAg-positive patients with an HBV DNA
level > 20,000 IU/mL and serum ALT > 80 IU/L, and all
HBeAg-positive patients with an ALT > 5 the upper limit of
normal (ULN)] from January 2009 to December 2010. Pa-
tients were eligible for recruitment in this study if they
were aged  20 years and had chronic HBV that was treated
with LAM, ETV, or LdT for 3 years. Patients with a coexisting
hepatitis C virus infection, liver decompensation, or auto-
immune disease; change in nucleos(t)ide; or malignancy,
and those who were lost during follow-up were excluded.
The definition of liver decompensation is cirrhosis compli-
cated with splenomegaly, esophageal varices, gastric vari-
ces, jaundice (total bilirubin  2 mg/dL), or coagulopathy
(prolonged prothrombin time  3 seconds). The recruited
HBV patients in this study were divided into those who
continued treatment beyond 3 years and those who stopped
by patients’ willingness after 3 years of treatment; all pa-
tients submitted to a follow-up exam every 3 months for
1 year. Clinical relapse was defined as an increase in serum
HBV DNA level > 2000 IU/mL and a serum ALT level > 2
the ULN [1].
Age, sex, prior treatment, presence of cirrhosis, base-
line biochemical data, and serum HBV viral load were
recorded. Treatment was provided according to the Taiwan
NHI clinical practice that dictates a regular follow-up
abdominal echo and serum HBV DNA every 6 months dur-
ing treatment, checking of serum HBV DNA, aspartate
aminotransferase (normal range, 15e41 IU/L), and ALT
(normal range, 14e40 IU/L) levels every 3e6 months for
1 year after the 3-year mark. The patients were treated
with add-on ADV or switched to ETV 1 mg for 3 years if
clinical viral breakthrough occurred. The definition of viral
breakthrough was a serum HBV DNA level that increased > 1
log (IU/mL) over the previous serum level. The consolida-
tion duration was calculated from the first demonstration
of undetectable HBV DNA to the end of treatment.
Biochemical and efficacy analysis
The serum ALT and aspartate-aminotransferase ULN was set
by the laboratory at 40 U/L and 41 U/L (UniCel DxC 800,
Beckman Coulter, Inc., CA, USA), respectively, for men and
women; HBV DNA was measured by a Roche AMPLICOR po-
lymerase-chain-reaction assay (COBAS-AM test; Roche
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Figure 1. Clinical flow diagram of the 266 enrolled patients
with chronic hepatitis B virus. Of the 210 patients who
completed 3 years of treatment, 102 continued treatment and
88 stopped treatment and were followed up for 1 year.
E Z entecavir; HBV Z hepatitis B virus; HIV Z human immu-
nodeficiency virus; L Z lamivudine; T Z telbivudine.
12 C.-C. Lin et al.Molecular Systems, Pleasanton, California, USA) with a
lower limit of detection and quantitation of 20 IU/mL.
Serum hepatitis markers, including HBsAg, hepatitis B sur-
face antibody, HBeAg, hepatitis B e-antibody (chemilumi-
nescent microparticle immunoassay, ARCHITECT; Abbott,
Abbott Laboratories, Abbott Park, Illinois, U.S.A.), and anti-
hepatitis C virus were tested. Patients who completed
3 years of oral nucleos(t)ide analogue treatment with a
consolidation duration > 1 year in the clinical-relapse group
were included in the analysis. The end points were real-
world efficacy and virus-breakthrough rates of LAM, ETV,
and LdT, and we compared the clinical data between the
clinical-relapse and nonrelapse groups.
Statistical analysis
Categorical variables were compared using the Chi-square
test or Fisher’s exact test for each patient characteristic
category, while continuous variables were compared with
Student t test. The statistical analyses were performed
using the SPSS version 12.0 statistical package (SPSS Inc.,
Chicago, IL, USA). Missing data were treated using the SPSS
Missing Values option. All of the statistical analyses were
based on two-sided hypothesis tests with a significance
level of p < 0.05.
Consent
A written informed consent was obtained from the patients
for publication of this article and any accompanying
images.
Results
A total of 266 adult patients with chronic HBV were treated
with a nucleos(t)ide analogue (ETV, LAM, LdT) in this study;
of them, 210 patients completed the full 3-year course. The
patients were divided into those who continued treatment
(n Z 102) and those who stopped the drug with 1 year of
follow-up (n Z 88), and then further divided into the
clinical-relapse (n Z 27) and nonrelapse (n Z 53) groups
(Figure 1). The clinical-relapse rate of the 3-year treatment
course with 1 year of follow-up under the Taiwan NHI
clinical practice guideline was 31.9% (15/47) in the ETV
group, 35.7% (5/14) in the LAM group, and 36.8% (7/19) in
the LdT group. The average clinical-relapse rate was 33.8%.
If we analyzed the clinical-relapse rate in these 80 patients
between HBeAg positive and HBeAg negative, there was no
significant difference (12/33 vs. 15/47; p Z 0.679).
The baseline demographic and clinical characteristics of
the patients with chronic HBV in the clinical-relapse group
(nZ 27) and nonrelapse group (nZ 53) were similar in sex
proportion, mean age, baseline HBV DNA, and baseline ALT.
There was no significant difference between these two
groups in baseline HBeAg-positive rate, prior treatment
rate, liver-cirrhosis percentage, or treatment drugs (Table
1). The diagnostic criteria of liver cirrhosis are by abdom-
inal sonography, and we have excluded the decompensated
liver, including splenomegaly, esophageal varices, and
gastric varices who need long-term nucleoside-analogue
therapy without the limitation of 3 years by the Taiwan NHI.The distribution of 1-year off-therapy clinical-relapse per-
centages among these three nucleos(t)ide analogues
showed that 40% of ETV relapses occurred in Months 6e9,
60% of LAM relapses occurred in Months 1e3, and 43% of LdT
relapses occurred in Months 1e3 (Figure 2). No cases of
liver decompensation occurred during the 1-year follow-up
period.
In this study, there were 88 patients who completed
three-year treatment and then stopped the drug for 1 year,
the serum ALT level during the 3 years of antiviral treat-
ment, there was significant difference in the 3rd year ALT
serum level between clinical-relapse and clinical non-
relapse patients (37.5 U/L vs. 27.7 U/L; p Z 0.044,
Figure 3A). Upon the division of all patients into consoli-
dation duration > 1 year group (n Z 80) and < 1 year
(nZ 8) group, there was a trend of normal ALT since the 6th
month of treatment in the consolidation duration > 1 year
group (Figure 3B).
Table 1 Comparisons of baseline and end-of-therapy pa-
rameters between relapsers and nonrelapsers.
Nonrelapsers
(n Z 53)
Relapsers
(n Z 27)
p
Male 42 (79.2) 23 (85.2) 0.520
Age (y) 43.5  12.5 48.6  13.7 0.098
HBV DNA (base,
105 IU/mL)
150  230 170  240 0.753
ALT (base, IU/L) 246.7  272.4 231.3  174.9 0.790
HBeAg (positive) 21 (39.6) 12 (44.4) 0.679
Prior treatment 9 (17.0) 3 (11.1) 0.487
Drug (E/L/T) 32/9/12 15/5/7 0.916
Liver cirrhosis 7 (13.2) 4 (14.8) 0.844
ALT (end, IU/L) 26.3  12.3 28.9  18.3 0.450
AST (end, IU/L) 23.5  10.3 28.9  14.1 0.059
Data are presented as n (%) or mean  standard deviation,
unless otherwise indicated.
ALT Z alanine aminotransferase; AST Z aspartate amino-
transferase; base Z baseline; E Z entecavir; end Z end of
therapy; HBV Z hepatitis B virus; L Z lamivudine;
T Z telbivudine.
Off-treatment durability and predictors in HBV 13Discussion
The oral nucleos(t)ide analogues have good antiviral effects
during the treatment period, but tend to have poor dura-
bility after therapy discontinuation. According to previous
studies, in HBeAg-negative patients, the durability of
30 months of LAM treatment had a 1-year off-therapy
hepatitis flare rate of 43.6% [7]. Wang et al. [8] stated
that the durability of 3-year LAM treatment in HBeAg-
positive patients had a 1-year off-therapy virological
relapse rate of 35%. For LdT, the 60-month durability after
off-treatment had a clinical-relapse rate of 16.3%, and no
difference was found between HBeAg-positive and HBeAg-
negative patients [9]. Concerning ETV therapy, HBeAg-
negative patients treated for > 2 years still had a 74.2%
virological relapse rate after stopping the drug for 1 year
[10]. Dai et al. [11] reported that consolidation therapy forEntecavir Lamivudine Telbivudine
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Figure 2. Off-therapy 1-year clinical-relapse percentage
distribution of different nucleos(t)ide analogues.more than 18 months significantly improved the outcome of
LAM therapy, particularly for patients who achieved a
combined response after 6 months. Jeng et al. [12] also
reported that the off-therapy 1-year durability of ETV in
HBeAg-negative patients had a 45% clinical-relapse rate. In
our study, we found that 3-year ETV (31.96%), LAM (35.7%),
and LdT (36.8%) had similar 1-year off-therapy clinical-
relapse rates that might be due to the Taiwan NHI clinical
practice guideline that covered ADV or ETV 1 mg to keep
continuing treatment when viral breakthrough occurred.
Concerning chronic HBV treatment efficacy, Yao et al.
[13] stated that 74% of ETV-treated and 41% of LAM-treated
patients had HBV DNA clearance at the end of 2 years of
treatment, and that 96% of ETV-treated patients and 82% of
LAM-treated patients had normalized ALT. This result is like
ours, and showed that ETV had the best antiviral efficacy,
but not in ALT normalization among the three drugs.Figure 3. Serum alanine-aminotransferase level during the
3 years of antiviral treatment between clinical-relapse and
nonrelapse patients. [C: consolidation duration > 1 year group
(nZ 80); U: consolidation duration < 1 year group (nZ 8)]. (A)
The serum alanine-aminotransferase level between relapse
patients and nonrelapse patients during 3 years antivirus
treatment; and (B) there was a trend of normal alanine
aminotransferase since the 6th month treatment in consolida-
tion duration > 1 year group. ALTZ alanine aminotransferase.
14 C.-C. Lin et al.Concerning LAM and LdT resistances, the strategy of ADV
add-on therapy (22.6%) or a switch to ETV 1 mg (19.5%) was
not satisfied in HBeAg-positive hepatitis B patients because
a low virological response was observed at Month 12 [14].
Patients with chronic HBV treated with a low-genetic-
barrier nucleos(t)ide analogue may experience drug
resistance even in the 1st year of therapy. According to a
previous study, the incidence of LAM resistance increased
from 24% in 1 year to 70% in 5 years [15]. The risk of LdT
resistance was lower than that with LAM in the interna-
tional (GLOBE) and China Phase III studies; the 2-year risk
of resistance was 25.1% in HBeAg-positive patients and
10.8% in HBeAg-negative patients [16]. ETV resistance is
very rare; the cumulative probability of ETV resistance
was only 1.2% after 5 years of ETV treatment [17]. In this
study, the viral breakthrough data are similar to those of
previous studies. Concerning the time of clinical-relapse
onset after off-therapy, it most frequently occurred for
LAM and LdT in the 1ste3rd months, and for ETV in the
6the9th months. This result reconfirmed the previously
reported data [11].
Some factors are associated with chronic HBV disease
progression, including age, sex, HBV genotype, HBV DNA
serum viral load, treatment duration, and HBeAg, but which
factors are correlated with off-therapy clinical relapse
remain unknown. In one recent study of LdT off-treatment
durability, no significant difference was found in baseline or
on-treatment factors between cumulative clinical-relapse
rates of HBeAg positive and HBeAg negative [9]. Kim et al.
[18] reported that age, especially > 40 years, was a sig-
nificant predictor of both early and delayed relapse in
HBeAg-positive patients with chronic HBV treated with
LAM. In this study, we found that the mean age in the
clinical-relapse group (49 years) was higher than that of the
nonrelapse group (44 years), although the difference was
not statistically significant (p Z 0.098), but it might be
considered a risk factor of clinical relapse (Table 1).
The opinions concerning when to stop nucleos(t)ide
analogue treatment differ between Eastern and Western
countries. In the West, the goal of chronic HBV treatment is
to achieve seroclearance of HBsAg, so HBeAg-positive pa-
tients could discontinue nucleos(t)ide analogue treatment
if they achieved HBeAg seroclearance and maintain unde-
tectable HBV DNA levels. For HBeAg-negative patients,
stopping nucleos(t)ide analogue therapy is not recom-
mended [19]. In the Asian-Pacific area, the rule in HBeAg-
positive patients is similar to that in the West, but HBeAg-
negative patients need to demonstrate undetectable HBV
DNA levels for > 1 year, because cost is an important factor
in the selection of treatment strategy [1].
Here, we demonstrated that the patients with consoli-
dation duration > 1 year had early normal serum ALT
6 months after the initiation of treatment, but careful
consideration is needed before antiviral therapy is modified
with early suboptimal virological response to ETV due to the
majority of them achieving HBV DNA clearance [20]. By
contrast, the 88 off-therapy chronic hepatitis B patients
who experienced clinical relapse had a relatively high
normal average ALT (37.5 U/L) than the nonrelapse patients
(ALT 27.7 U/L, p < 0.05), but whether the 3rd year serum
ALT level could be a predictor of clinical relapse warrants
further evaluation.Our study had numerous limitations. First, it was a
retrospective cohort study and included only a small sample
of HBV off-therapy patients. Second, tests for HBV geno-
type and mutation are not currently available under the
Taiwanese NHI budget. In conclusion, this study showed
that patients with chronic HBV in Taiwan, whether HBeAg
positive or HBeAg negative, who completed 3 years of oral
nucleos(t)ide analogue treatment with an HBV DNA
consolidation duration > 1 year had a mean 33.8% 1-year
clinical-relapse rate without any liver decompensated
hepatitis flare-ups.Acknowledgments
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